Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5'-diphosphate (ADP) in human platelets

British Journal of Pharmacology

Volumn 127, Issue 6, 1999, Pages 1359-1366

  Park, Hye Seong ^a   Hourani, Susanna M O ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

ADP; Aggregation; ATP; Human platelets; P2 receptors; shape change

Indexed keywords

2 METHYLTHIOADENOSINE TRIPHOSPHATE; ADENINE NUCLEOTIDE; ADENOSINE 5' O (2 THIODIPHOSPHATE); ADENOSINE 5' O (3 THIOTRIPHOSPHATE); ADENOSINE DIPHOSPHATE; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; DIADENOSINE PENTAPHOSPHATE; PURINE P2Y RECEPTOR; URIDINE TRIPHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOCYTE SHAPE;

ADENINE NUCLEOTIDES; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BLOOD PLATELETS; CELL SIZE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION; SURAMIN; THIONUCLEOTIDES; TRYPANOCIDAL AGENTS; URIDINE TRIPHOSPHATE;

EID: 0032767412     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702690     Document Type: Article

References (38)

1. 1 receptor. Mol. Pharmacol., 50, 1323-1329.
2. Colman, R.W. (1992). Platelet ADP receptors stimulating shape change and inhibiting adenylate cyclase. News Physiol, Sci., 7, 274-278.
3. Cusack, N.J. & Hourani, S.M.O. (1981a). Partial agonist behaviour of adenosine 5′-O-(2-thiodiphosphate) on human platelets. Br. J. Pharmacol., 73, 405-408.
4. Cusack, N.J. & Hourani, S.M.O. (1981b). Effects of Rp and Sp diastereoisomers of adenosine 5′-O-(1-thiodiphosphate) on human platelets. Br. J. Pharmacol., 73, 409-412.
5. Cusack, N.J. & Hourani, S.M.O. (1982a). Adenosine 5′-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol., 76, 221-227.
6. Cusack, N.J. & Hourani, S.M.O. (1982b). Competitive inhibition by adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate. Br. J. Pharmacol., 77, 329-333.
7. Cusack, N.J. & Hourani, S.M.O. (1982c). Specific but non-competitive inhibition by 2-alkylthio analogues of adenosine 5′-monophosphate and adenosine 5′-triphosphate of human platelet aggregation induced by adenosine 5-diphosphate. Br. J. Pharmacol., 75, 391-400.
8. Daniel, J.L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J.B. & Kunapuli, S.P. (1998). Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem., 273, 2024-2029.
9. ADP-receptors. Br. J. Pharmacol., 124, 157 164.
10. 2Y purinergic receptor that couples to phospholipase C. Mol. Pharmacol., 46, 8-14.
11. Gachet, C., Hechler, B., Léon, C., Vial, C., Ohlmann, P. & Cazenave, J.-P. (1996). Purinergic receptors on blood platelets. Platelets, 7, 261-267.
12. Geiger, J., Honig-Liedl, P., Schanzenbacher, P. & Walter, U. (1998). Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur. J. Pharmacol., 351, 235-246.
13. Hall, D.A., Frost, V. & Hourani, S.M.O. (1994). Effects of extracellular divalent cations on responses of human blood platelets to adenosine 5′-diphosphate. Biochem. Pharmacol., 48, 1319-1326.
14. 2T purinoceptors on human blood platelets Br. J. Pharmacol., 108, 728-733.
15. Hall, D.A. & Hourani, S.M.O. (1994). Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5′-diphosphate in human platelets. Biochem. Pharmacol., 47, 1013-1018.
16. Haslam, R.J. & Rosson, G.M. (1975). Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol. Pharmacol., 11, 528-544.
17. 1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood, 92, 152-159.
18. 1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol., 53, 727-733.
19. Hourani, S.M.O., Divirgilio, F. & Loubatiéres-Mariani, M.-M. (1998). Physiological roles of P2 receptors in platelets, visceral smooth muscle and the immune and endocrine systems. In The P2 Nucleotide Receptors. eds. Turner, J.T., Weisman, G.A. & Fedan, J.S. pp. 361-411. Totowa NJ: Humana Press.
20. Hourani, S.M.O. & Hall, D.A. (1994). ADP receptors on human blood platelets. Trends Pharmacol. Sci. 15, 103-108.
21. 2T-Purinoceptors: ADP receptors on platelets. In P2 Purinoceptors: Localization, Function and Transduction Mechanisms. Ciba Foundation Symposium. 198. eds. Chadwick, D.J. & Goode, J.A., pp. 53-70. Chichester: Wiley.
22. 2-purinoceptor antagonist suramin on human platelet aggregation induced by adenosine 5′-diphosphate. Br. J. Pharmacol., 105, 453-457.
23. Hourani, S.M.O., Welford, L.A. & Cusack, N.J. (1986). 2-MeS-AMP-PCP and human platelets: implications for the role of adenylate cyclase in ADP-induced aggregation. Br. J. Pharmacol., 87, 84P.
24. Hourani, S.M.O., Welford, L.A. & Cusack, N.J. (1996). Effects of 2-methylthioadenosine 5′-β,γ-methylenetriphosphonate and 2-ethylthioadenosine 5′-monophosphate on human platelet activation induced by adenosine 5′-diphosphate. Drug Dev. Res., 38, 12-23.
25. 2T-purinoceptors. Br. J. Pharmacol., 113, 1057-1063.
26. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci., 16, 179-181.
27. 2T receptors. Br. J. Pharmacol., 124, 32P.
28. Jin, J., Daniel, J.L. & Kunapuli, S.P. (1998). Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem., 273, 2030-2034.
29. Jin, J. & Kunapuli, S.P. (1998). Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. U.S.A., 95, 8070-8074.
30. Kunapuli, S.P. (1998). Multiple P2 receptor subtypes on platelets: a new interpretion of their function. Trends Pharmacol. Sci., 19, 391-394.
31. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Letts, 403, 26-30.
32. Mills, D.C.B. (1996). ADP receptors on platelets. Thrombos. Haemostas.,76, 835-856.
33. Park, H.-S. & Hourani, S.M.O. (1998). Different effects of analogues of adenine nucleotides on aggregation and shape change mediated by adenosine 5′-diphosphate receptors on human platelets. Drug Dev. Res., 43, 48.
34. Park, H.-S, & Hourani, S.M.O. (1999). Different effects of adenine nucleotide analogues on the responses mediated by adenosine 5′ diphosphate (ADP) receptors on human platelets. Br. J. Pharmacol., 126, 196P.
35. Park, H.-S., Tennant, J.P., Waktolla, G.F., Sarkardei, S., Kass, G.E.N. & Hourani, S.M.O. (1998). Effects of adenosine 3′-phosphate 5′-phosphosulphate on P2 receptors in platelets and smooth muscle preparations. Drug Dev. Res., 45, 67-73.
36. Sanderson, H.M., Heptinstall, S., Vickers, J. & Lösche, W. (1996). Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. Blood Coagulation Fibrinolysis, 7, 245-248.
37. Savi, P., Beauverger, P., Labouret, C., Delfaud, M., Salel, V., Kaghad, M. & Herbert, J.M. (1998). Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Letts, 422, 291-295.
38. 1 purinoceptors in human platelets and megakaryoblastic cell lines. Thrombos. Haemostas., 78, 1500-1504.